Lipocine announces distribution and license agreement with spc korea to commercialize tlando® in south korea

Salt lake city , oct. 31, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced a license, development and supply agreement with to spc korea http://spcpharm.co.kr granting exclusive rights to market tlando® in south korea. under the terms of the distribution and license agreement, lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including a payment upon regulatory approval of tlando in south korea.
LPCN Ratings Summary
LPCN Quant Ranking